The first men in the UK have begun taking part in a major prostate cancer screening study that could transform how the disease is detected and diagnosed. The study is the largest prostate cancer screening trial launched in decades and aims to identify the most effective way to screen men for the disease.
Prostate cancer is the most common cancer in men in the UK, yet there is currently no national screening programme. This is partly because existing tests, such as the prostate-specific antigen (PSA) blood test, are not always reliable enough on their own. They can sometimes miss aggressive cancers or detect slow-growing cancers that may never cause harm. The TRANSFORM trial aims to address these challenges by evaluating new and more accurate approaches to screening.
The trial will explore a range of potential screening methods and combinations to determine which are most effective. In the first phase, around 16,000 men will be invited to take part through letters sent by their GP practices. Participants will help researchers test different screening approaches, including PSA blood tests, genetic saliva tests and faster MRI scans. These methods will be compared with current NHS diagnostic pathways to assess their accuracy and effectiveness.
Men aged between 50 and 74 will be invited to participate, reflecting how a future national screening programme might operate. Some groups at higher risk of prostate cancer, including Black men, may be invited from the age of 45 to ensure the study captures data from those most affected by the disease.
Following the pilot phase, the most promising screening approaches will be tested in a much larger group of up to 300,000 men across the UK. Researchers hope the findings will provide the evidence needed to determine whether a national screening programme could be introduced.
As well as improving early diagnosis, the trial will also create a valuable collection of prostate cancer data, images and biological samples. This resource could support future research and help develop new diagnostic tests and treatments, ultimately improving outcomes for patients.
Jaroslaw Galik, 55, from London, one of the first men tested, said:
“I’d heard a bit about prostate cancer over the years and had always thought I should probably speak to my GP, but I never actually got round to doing anything about it. There isn’t that routine screening programme, so it just wasn’t something that felt urgent.
“When the letter about TRANSFORM came through, I realised this was a straightforward way to check my own risk while also contributing to something bigger. If taking part helps move us closer to having a proper screening programme in the future, so men are just invited by their GP like they are for other cancers that would make such a difference. To think that just by taking a couple of tests I could be helping to finally get to screening and save thousands of lives is incredible.”
Professor Hashim Ahmed, Chief Investigator of the TRANSFORM trial and Chair of Urology at Imperial College Healthcare NHS Trust and Professor of Urology at Imperial College London said:
"The men tested today mark the start of the biggest prostate cancer screening trial in over 2 decades. The size and quality of TRANSFORM means the data we’re collecting now will help us make prostate cancer diagnosis far safer and more effective for all men at risk, and will inform lifesaving research for decades to come.
“By testing cutting edge techniques, including blood tests, genetics, and MRI scans, we can find the best way to screen men for the disease and save thousands of lives each year.”
The £42 million study is being delivered in partnership with the NHS and is jointly funded by the National Institute for Health and Care Research (NIHR) and Prostate Cancer UK.
For more information, please read the original article on the NIHR news site: First men tested in pioneering prostate cancer screening trial | NIHR
Image: MART PRODUCTION